- Home
- WOLF vs LRMR Comparison
WOLF vs LRMR Comparison
Compare WOLF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | LRMR |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 455.8M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WOLF | LRMR |
|---|---|---|
| Price | $17.01 | $4.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $12.75 | ★ $16.29 |
| AVG Volume (30 Days) | 1.3M | ★ 6.6M |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $1.61 |
| 52 Week High | $36.60 | $6.42 |
Technical Indicators
Market Signals| Indicator | WOLF | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 50.13 |
| Support Level | $16.64 | $3.13 |
| Resistance Level | $22.59 | $6.21 |
| Average True Range (ATR) | 1.62 | 0.42 |
| MACD | -0.18 | -0.15 |
| Stochastic Oscillator | 22.06 | 18.06 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.